Adjuvant analgesics • Neuropathic pain • Bone pain • Spasm • Bowel obstruction • Palliative care

Adjuvant Analgesics in Palliative Pain Management

Mechanisms, indications, supervised doses, contraindications, interactions and monitoring

Learning objectives

• Define adjuvant or co-analgesic medicines and explain their role alongside analgesics.
• Match adjuvant classes to neuropathic, inflammatory, bone, visceral, spastic and opioid-related pain.
• Explain mechanisms, common adult examples, dosing principles, contraindications, adverse effects, interactions and monitoring.
• Use a safe start–titrate–review–stop process and recognize treatment failure or toxicity.
• Integrate pharmacological adjuvants with opioids, non-drug care, nursing assessment and emergency escalation.

1. What is an adjuvant analgesic?

An adjuvant (co-analgesic) is a medicine developed primarily for a non-pain indication that has independent analgesic activity, enhances an analgesic, targets a particular pain mechanism or reduces an analgesic’s adverse effects. The supplied reference emphasizes that adjuvants can be used at all steps of the WHO ladder.

Most adjuvants have a ceiling to their analgesic benefit, while some have delayed onset, narrow safety margins or potentially permanent organ toxicity. Do not add several new drugs at once unless an emergency requires it; otherwise, it becomes difficult to identify benefit or harm.

2. Mechanism-based classification

Category	Examples	Typical targets
Multipurpose/nonspecific	Corticosteroids, antidepressants, alpha-2 agonists.	Inflammation, nerve compression, mood/sleep, central modulation and mixed pain.
Neuropathic-pain specific	TCAs, SNRIs, gabapentinoids, selected anticonvulsants, local anaesthetics, ketamine.	Ectopic nerve firing, calcium-channel signaling, descending modulation, central sensitization and NMDA-mediated wind-up.
Bone pain	Corticosteroids, bisphosphonates, denosumab where available, calcitonin, radiotherapy.	Inflammation, osteoclast activity, pathological fracture and tumour-related bone remodeling.
Muscle spasm/spasticity	Baclofen, selected muscle relaxants, benzodiazepines only with specialist caution.	Skeletal-muscle overactivity or spinal spasticity.
Colic or bowel obstruction	Antispasmodics, octreotide, antisecretory agents, antiemetics and corticosteroids in selected cases.	Smooth-muscle spasm, gastrointestinal secretion, distension and nausea.
Opioid adverse effects	Laxatives, antiemetics, dose/route review and selected opioid antagonists.	Constipation, nausea, pruritus or toxicity; treat the cause, not only the symptom.

3. A safe adjuvant prescribing process

1. Confirm the pain mechanism: burning/electric pain with sensory change suggests neuropathic involvement; inflammatory, bone, colicky and spastic patterns need different strategies. Mixed mechanisms are common.
2. Exclude emergencies: new weakness, bowel/bladder dysfunction, sepsis, fracture, obstruction, bleeding, severe hypoxia, delirium or rapidly escalating pain require urgent assessment.
3. Set a measurable goal: sleep, walking, dressing, turning, breathing, feeding or reduced breakthrough episodes.
4. Review the patient: age, frailty, renal/hepatic function, ECG risk, pregnancy, glaucoma, urinary retention, seizures, mood, substance use and current medicines.
5. Start one agent low: use a clear titration and review date; explain expected onset and common effects.
6. Monitor: pain and function, alertness, falls, mood, organ toxicity, vital signs and laboratory tests when required.
7. Stop or change: discontinue gradually where withdrawal is possible, or seek specialist advice for serious toxicity, no meaningful benefit or an unsafe interaction.

4. Corticosteroids

Mechanism and indications

Dexamethasone reduces inflammatory mediators, tissue edema and nerve compression. It may help pain from spinal or nerve compression, raised intracranial pressure, capsular liver stretch, inflammatory pain, selected bone pain, nausea and appetite loss. It is not a universal analgesic.

Aspect	Detailed guidance
Educational adult dose	Indication-specific; commonly 2–8 mg orally or parenterally in the morning for a short course. The supplied reference describes a broader 2–20 mg/day range; higher doses require specialist oversight.
Benefits	May reduce edema, pressure, inflammation, nausea and pain, often within hours to days.
Contraindications/cautions	Untreated systemic infection, uncontrolled diabetes, severe psychosis, active gastrointestinal ulcer, high fracture risk and prolonged use without review.
Adverse effects	Hyperglycaemia, insomnia, agitation, steroid psychosis, proximal myopathy, dyspepsia, infection, fluid effects, skin changes and adrenal suppression.
Interactions	NSAIDs increase gastrointestinal risk; vaccines, anticoagulants, antidiabetics, CYP3A4 medicines and other immunosuppressants require review.
Monitoring	Glucose, infection, mood, sleep, muscle strength, gastrointestinal symptoms, blood pressure, function and ongoing indication. Taper after prolonged treatment.

5. Antidepressants for neuropathic pain

5.1 Tricyclic antidepressants

Amitriptyline and nortriptyline inhibit serotonin and noradrenaline reuptake and block sodium and other channels, enhancing descending inhibition and reducing ectopic nerve activity.

Medicine and example	Indications	Risks, contraindications and monitoring
Amitriptyline: often start 10–25 mg at night; increase slowly every several days to weekly. Many services use 25–75 mg at night; higher or divided doses need specialist review.	Peripheral neuropathic pain, dysaesthesia, sleep disturbance and selected visceral neuropathic pain.	Dry mouth, constipation, blurred vision, urinary retention, postural hypotension, sedation, falls, delirium and QT prolongation. Avoid or obtain ECG/senior advice in significant conduction disease, recent infarction, severe glaucoma or urinary retention. Response may begin within days but allow an adequate monitored trial.
Nortriptyline: start low, commonly 10–25 mg at night and titrate cautiously.	Neuropathic pain when a less sedating or less anticholinergic TCA is preferred.	Similar cardiac and anticholinergic cautions; review interacting serotonergic medicines and overdose risk.

Use caution in older adults because sedation and orthostatic effects increase falls. Do not stop abruptly after sustained high-dose use without advice.

5.2 SNRIs

Duloxetine and venlafaxine enhance descending noradrenergic and serotonergic inhibition.

• Duloxetine: commonly 30 mg once daily initially, increasing to 60 mg daily if tolerated for diabetic neuropathic pain or selected mixed pain.
• Cautions: nausea, dizziness, insomnia or somnolence, blood-pressure change, sexual adverse effects, withdrawal, serotonin syndrome and liver injury risk. Avoid severe hepatic disease and review renal function.
• Interactions: MAOIs, other serotonergic medicines, tramadol, linezolid and some migraine medicines can increase serotonin toxicity.

6. Anticonvulsants and gabapentinoids

6.1 Gabapentin

Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory transmitter release. It is structurally related to GABA but does not act as a GABA agonist.

• Example adult start: 100–300 mg at night, then increase gradually to twice- or three-times-daily dosing as tolerated. Some protocols use 300–600 mg three times daily; the maximum and titration interval depend on indication and renal function.
• Indications: peripheral neuropathic pain, allodynia and selected cancer or HIV neuropathies.
• Adverse effects: drowsiness, dizziness, ataxia, peripheral oedema, blurred vision, weight gain, mood change and falls.
• Interactions: additive sedation and respiratory depression with opioids, alcohol, benzodiazepines and other CNS depressants.
• Monitoring: renal function, alertness, gait, oedema, respiratory status, benefit and misuse risk. Adjust in renal insufficiency.

6.2 Pregabalin

Pregabalin binds the same alpha-2-delta calcium-channel subunit with more predictable absorption than gabapentin.

• Example adult start: 25–75 mg once or twice daily, titrated according to response and renal function; many protocols use 75 mg twice daily after initiation.
• Indications: neuropathic pain, allodynia and selected anxiety/sleep symptoms.
• Adverse effects: dizziness, somnolence, blurred vision, oedema, weight gain, constipation, mood change and misuse.
• Interactions: additive sedation and breathing risk with opioids, alcohol and sedatives.
• Monitoring: renal function, falls, cognition, breathing, oedema, function and withdrawal if stopped abruptly.

6.3 Carbamazepine, valproate and clonazepam

Medicine	Possible role	Critical precautions
Carbamazepine	Particularly useful in trigeminal neuralgia and selected neuropathic syndromes.	Start low, often 100 mg twice daily under specialist/local protocol; titrate with full blood count, liver tests, sodium and drug-interaction review. Rash, Stevens–Johnson syndrome, ataxia, diplopia, hyponatraemia and blood dyscrasias can occur. It induces hepatic enzymes and changes many medicines.
Sodium valproate	Specialist/off-label option for selected neuropathic pain or seizure-related conditions.	Hepatotoxicity, pancreatitis, thrombocytopenia, tremor, weight gain, sedation and major pregnancy/teratogenic risk. Check liver tests, blood count, interactions and current regulatory guidance.
Clonazepam	Occasionally considered for severe spasm, anxiety or myoclonus under specialist care.	Dependence, falls, delirium and respiratory depression—especially with opioids. Avoid routine use for neuropathic pain and do not stop abruptly after regular use.

7. NMDA antagonists and local anaesthetics

7.1 Ketamine

Ketamine antagonizes NMDA receptors and may reduce central sensitization, opioid-induced hyperalgesia and severe refractory pain. Low-dose ketamine is better described as anti-hyperalgesic or anti-allodynic in some settings; it is not a routine first-line analgesic.

• Use: specialist palliative, anaesthetic or pain-team rescue when standard multimodal therapy fails.
• Educational example: perioperative literature includes subanaesthetic doses such as 0.15 mg/kg in selected protocols; route, bolus and infusion regimens vary and must be prescribed by trained clinicians.
• Adverse effects: hallucinations, nightmares, dysphoria, nausea, vomiting, dizziness, urinary symptoms, hypertension, tachycardia and excessive sedation.
• Contraindications/cautions: uncontrolled psychosis, severe hypertension, raised intracranial/intraocular pressure concerns, serious cardiovascular disease and inability to monitor airway or mental state.

7.2 Lidocaine and regional techniques

Topical lidocaine may help focal peripheral neuropathic pain on intact skin. Intravenous lidocaine, nerve blocks, epidural or intrathecal techniques require trained specialists, monitoring and resuscitation capability. Toxicity may cause perioral numbness, metallic taste, tinnitus, agitation, seizures, hypotension, arrhythmia or cardiovascular collapse.

8. Alpha-2 agonists

Clonidine reduces sympathetic outflow and can modulate spinal pain transmission, including A-delta and C-fibre pathways. Dexmedetomidine is more alpha-2 selective and shorter acting, but both are specialist medicines in analgesia.

• Uses: selected neuraxial or perioperative analgesia, autonomic hyperactivity, withdrawal or refractory pain under specialist care.
• Educational reference: perioperative clonidine around 1 microgram/kg has been described, but route and haemodynamic context are crucial.
• Adverse effects: hypotension, bradycardia, sedation, dry mouth and rebound hypertension if stopped suddenly.
• Monitoring: continuous or frequent blood pressure, pulse, respiratory status, level of consciousness and withdrawal risk.

9. Bone-pain adjuvants

Bisphosphonates

Zoledronic acid and pamidronate inhibit osteoclast-mediated bone resorption and may reduce pain and skeletal complications from selected bone metastases or myeloma. They are not immediate rescue analgesics.

• Examples: zoledronic acid 4 mg IV over at least 15 minutes every 3–4 weeks, or pamidronate 60–90 mg IV at specialist intervals—verify indication and local protocol.
• Checks: renal function, calcium, vitamin D status, hydration, dental health and concurrent nephrotoxins.
• Risks: acute-phase fever/aches, hypocalcaemia, renal injury, osteonecrosis of the jaw and atypical fractures.

Other options

Radiotherapy can provide effective focal relief for painful metastases; calcitonin may have a role in selected acute vertebral or bone pain; denosumab may be used where available and indicated. These require oncology, radiology or specialist review and do not replace assessment for pathological fracture or spinal cord compression.

10. Bowel obstruction, colic and secretion-related pain

Adjuvant	Role	Safety points
Antispasmodics	Hyoscine butylbromide, glycopyrrolate or related agents may reduce smooth-muscle spasm and secretions in selected obstruction or colic.	Anticholinergic delirium, urinary retention, dry mouth, blurred vision, tachycardia and glaucoma risk. Confirm the cause and involve senior care.
Octreotide	Reduces gastrointestinal secretions and vomiting in selected malignant bowel obstruction.	Specialist/local protocol; monitor glucose, gallbladder effects, bradycardia and injection-site effects.
Corticosteroid	May reduce bowel-wall or tumour edema in selected cases.	Infection, hyperglycaemia, delirium and gastrointestinal risks; do not delay surgical assessment where appropriate.
Antiemetic	Targets nausea and vomiting that worsen suffering or prevent oral analgesia.	Select according to cause; check QT, sedation, extrapyramidal and anticholinergic effects.

11. Adjuvants that prevent analgesic harm

• Opioid constipation: initiate a bowel plan unless obstruction is suspected; review stool frequency, pain, distension and vomiting.
• Opioid nausea: assess constipation, obstruction, vestibular, metabolic and medication causes before selecting an antiemetic.
• Gastroprotection: consider a proton-pump inhibitor when NSAID gastrointestinal risk warrants it.
• Sleep and anxiety: prioritize communication, psychological and non-drug approaches; avoid routine benzodiazepines with opioids.
• Itch or urinary retention: assess the opioid and alternative causes rather than adding multiple sedating medicines.

12. Combining adjuvants with opioids: practical rules

1. Keep one clear primary analgesic plan and add an adjuvant for a defined target.
2. Start low and titrate slowly, especially in older adults, renal impairment or respiratory disease.
3. Do not combine several sedating medicines without a monitoring plan.
4. Set a review date and a stop rule: no meaningful functional benefit, intolerable toxicity or a changed diagnosis.
5. Use the same pain tool and document mechanism, function, response, adverse effects and adherence.
6. Explain expected onset: some agents act within hours, others require days or weeks.

13. Nursing and caregiver responsibilities

• Record baseline pain, function, mechanism clues, medicines, allergies, renal/hepatic risk and goals.
• Check the exact medicine, strength, route, dose, timing and indication; do not assume an off-label medicine is familiar.
• Monitor alertness, respiratory rate, blood pressure, pulse, gait, falls, mood, bowel function, urine, glucose and laboratory tests as indicated.
• Teach the patient/caregiver why the adjuvant was added, when benefit is expected, what not to stop abruptly and which danger signs require help.
• Use a medicine reconciliation at every transition and identify interactions, duplicate sedatives and traditional medicines.
• Escalate hallucinations, severe rash, jaundice, muscle weakness, seizures, suicidal thinking, respiratory depression, uncontrolled pain or suspected overdose.

14. Emergency interface

15. Clinical cases

16. Quick self-test

1. What makes a medicine an adjuvant analgesic?
2. Give three neuropathic-pain adjuvants and one major safety issue for each.
3. When might dexamethasone be useful in palliative pain?
4. Why are ketamine and intravenous lidocaine specialist treatments?
5. Name three reasons an adjuvant plan may need review rather than escalation.
6. What should be monitored when gabapentinoids are combined with opioids?

Answers

1. It was developed mainly for another indication but has independent analgesic activity, enhances analgesia, targets a mechanism or reduces an analgesic adverse effect.
2. Examples: amitriptyline—anticholinergic/cardiac/falls risk; gabapentin—sedation, falls and renal clearance; pregabalin—sedation, oedema and breathing risk; carbamazepine—blood dyscrasias and interactions; duloxetine—serotonin/liver/renal cautions.
3. Nerve or spinal compression, inflammatory or capsular pain, raised intracranial pressure, selected bone pain, nausea or appetite loss under a defined protocol.
4. They can cause cardiovascular, neurological, psychiatric and airway complications and require specialist dosing, monitoring and rescue capability.
5. No functional benefit, serious toxicity, changed diagnosis, uncontrolled emergency, interaction, poor adherence, renal/hepatic change or frequent rescue doses.
6. Respiratory rate/effort, sedation, confusion, dizziness, gait/falls, renal function, oedema, mood and actual pain/function benefit.

Key take-home points

• Adjuvants are mechanism-directed partners, not a random collection of extra medicines.
• Neuropathic, bone, inflammatory, visceral and spastic pain require different targets, and mixed pain is common.
• Start low, titrate slowly, define a functional goal, monitor organ toxicity and stop when harm exceeds benefit.
• Gabapentinoids, TCAs, ketamine, clonidine and benzodiazepines can compound sedation and respiratory risk with opioids.
• Cause-directed treatment, nursing care, communication and safe follow-up are as important as the drug.

Further study and references

• Comprehensive Overview of Adjuvant Analgesic Drugs in Cancer Pain Management — supplied Slideshare reference
• WHO analgesic ladder and adjuvant therapies — supplied reference
• WHO cancer pain guideline
• NICE: Neuropathic pain in adults
• Related lesson: WHO analgesic ladder and pain management
• Related lesson: Oral morphine in palliative care and Uganda’s legal framework

Educational resource for supervised learning. Verify current Uganda formulary, controlled-medicine rules and specialist protocols before prescribing.